"As tradition holds, Celgene (CELG) gave the first presentation at the recent 29th JP Morgan Healthcare Conference, where CEO Bog Hugin focused on Celgene's ongoing plans to become a world-wide company and expansion into global markets," reports John McCamant.

The biotech specialist and editor of The Medical Technology Stock Letter explains, "They expect 2011 to be the first year where the company earns a majority of sales outside the U.S. The company is currently conducting 25 Phase III trials on its various drugs.

"Celgene also announced 4th quarter 2010 earnings last week, and revenue was down 16%, mostly based on costs incurred due to the Abraxis acquisition.

"After releasing their 3Q financials. the stock price at Isis Pharmacueticals (ISIS) perked up as their large cash position and deep pipeline have attracted some new investors," notes biotech expert John McCamant.

The editor of The Medical Technology Stock Letter explains, "When investors investigate the ISIS story and all its parts, they come away with an appreciation for all the potential long-term value being created at the company.

"We believe OncoGenex (OGXI) is undervalued relative to its peers," says biotech expert John McCamant.

The editor of The Medical Technology Stock Letter suggests, "One of the best ways to start evaluating development stage biotech stocks is to evaluate three fundamental considerations to begin the screening process. We ask, 'What is the market potential?' 'How long before the drug development candidate is likely to be approved?' and 'How much development risk remains?'

"Some sectors tend to do better than others in tough times; biotechnology often surprises investors in good times and bad," suggests Brandon Clay.

In his Invest with an Edge advisory service, the growth stock advisor looks to Celgene Corporation (NASDAQ: CELG), a player in developing cancer treatments. Here's his review.

"This sometimes-perilous market niche can make or break a portfolio depending on several factors: drug pipeline, continued investment, market factors, and government approvals.

"However, despite the risks, there are times when we believe that individual biotech stocks make sense -- such as our latest recommendation for Celgene.

"Biotech company Celgene Corp. (NASDAQ: CELG) is a prime example of a stock that plays both offense and defense," says Ian Wyatt.

In his Top Stock Insights, he explains, "The valuation is low and growth is attractive. With the pipeline of products in development, Celegene offers investors a huge upside potential."

"Celgene offers investors a steady product base, a variety of drug treatments in development and a cash pile ready to purchase existing technologies.

"Celgene engages in the discovery of therapies designed to treat cancer and immune-inflammatory related diseases. They have a number of products at the commercial stage.

"After warning that it would only achieve the low end of its previous guidance range for 2009, Celgene (NASDAQ: CELG) sold off significantly," notes biotech expert John McCamant.

Nevertheless, in his The Medical Technology Stock Letter he sees the selloff as any opportunity, calling the company a "great growth story."

"Celgene pre-announced 1Q 09 revenues of $600 million, which was significantly below Wall Street consensus estimates of $640-$650 million.

"The earnings miss was completely unexpected, and has partially shaken the belief that the Big Bios would be able to deliver solid earnings despite the economic problems.Nevertheless, we remain positive on the CELG story.

"Celgene (NASDAQ: CELG) reported their fourth quarter and year end numbers which showed strong revenue growth." observes biotech sector expert John McCamant.

The editor of The Medical Technology Stock Letter explains, "We remain excited about CELG's growth prospects and management's ability to deliver the goods.

"Total revenue for the quarter grew 50% to $623 million, with the primary driver being Revlimid sales of $369.4 million. Sales of their two other drugs, Thalomid and Vidaza generated $126.8 million and 69.7 million, respectively.

"Genentech (NYSE: DNA), the world leader in cancer treatment, has been weak following its third quarter earnings report," notes biotech sector expert John McCamant.

In his The Medical Technology Stock Letter, he explains, "What we are seeing with DNA's stock represents an irrational overreaction by Wall Street, and one that should be taken advantage of by investors."

The advisor notes, "Starting with their earnings, DNA reported non-GAAP operating revenues of $2.91 billion, and U.S. product sales of $2.2 billion, for the third quarter. These figures represent an increase of 22% and 18%, respectively, over the same figures reported during last year's third quarter.

"As such, we are pleased with the growth that DNA has continued to produce. However, because revenue came in a little shy of analysts' consensus expectation, the stock has sold off. We would note one glaring positive which DNA just isn't getting much credit for anymore. That is, even at its already huge size, the company still expects to produce impressive growth for the full year (and in the years to come)."